There remains a need to develop new treatments for pediatric patients with attention deficit hyperactivity disorder (ADHD), particularly in extended release formulations.
One such option could be viloxazine (Qelbree), which received U.S. Food and Drug Administration approval in April for pediatric ADHD patients ages 6 to 17.
In a double-blind study of 297 patients aged 12-17 years diagnosed with ADHD, researchers found that patients treated with viloxazine 400 mg treatment achieved statistical significance compared to placebo in the primary endpoint, change from baseline in ADHD -RS- 5 total score. Participants receiving study drug had a mean change of -18.3 LS from baseline (P = 0.0082) versus LS mean change from baseline of -13.2 for those receiving placebo.
In this episode of the DocTalk Podcast, Ann C. Childress, MD, Center for Psychiatry and Behavioral Medicine, explained the promising results of viloxazine and why it could be a game changer for pediatric ADHD patients.
Childress said the extended-release formulation should help reduce social stigma for students who take medications during the school day.
However, looking at the state of ADHD care, there are some reasons to remain concerned. Childress said there is still a need to develop new treatments, particularly for pediatric patients, and there is reason to believe this patient group may be particularly affected by the circumstances of the COVID-19 pandemic.